Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of <i>Mycobacterium tuberculosis</i>.

ABSTRACT: Increasing evidence supports the repositioning of beta-lactams for tuberculosis (TB) therapy, but further research on their interaction with conventional anti-TB agents is still warranted. Moreover, the complex cell envelope of Mycobacterium tuberculosis (Mtb) may pose an additional obstacle to beta-lactam diffusion. In this context, we aimed to identify synergies between beta-lactams and anti-TB drugs ethambutol (EMB) and isoniazid (INH) by assessing antimicrobial effects, intracellular activity, and immune responses. Checkerboard assays with H37Rv and eight clinical isolates, including four drug-resistant strains, exposed that only treatments containing EMB and beta-lactams achieved synergistic effects. Meanwhile, the standard EMB and INH association failed to produce any s

SUBMITTER: Olivenca F 

PROVIDER: S-EPMC10989012 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature